Free Trial

Skye Bioscience Q4 2024 Earnings Report

Skye Bioscience logo
$1.87 -0.25 (-11.79%)
As of 03/28/2025 04:00 PM Eastern

Skye Bioscience EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.06
One Year Ago EPS
-$0.36

Skye Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Skye Bioscience Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Skye Bioscience Earnings Headlines

Do this Before Elon's Reveal on April 23rd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Skye Bioscience price target lowered to $14 from $18 at Craig-Hallum
See More Skye Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email.

About Skye Bioscience

Skye Bioscience (NASDAQ:SKYE), a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

View Skye Bioscience Profile

More Earnings Resources from MarketBeat